Journal
KIDNEY INTERNATIONAL
Volume 90, Issue 3, Pages 474-476Publisher
NATURE PUBLISHING GROUP
DOI: 10.1016/j.kint.2016.05.024
Keywords
-
Categories
Ask authors/readers for more resources
Immune checkpoint inhibitors are a class of drugs that utilizes immunotherapy to target various cancers. Included are the anti-CTLA-4 and anti-PD-1 receptor antibodies. By reprogramming the immune system, these agents provide a therapy that destroys cancer cells. However, this approach runs the risk of allowing pathologic autoimmunity and organ injury to develop. Unsurprisingly, immune-related adverse effects are described including pneumonitis, colitis, and various endocrinopathies. Now added to this list is AKI, primarily due to ATIN.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available